Sarepta Shares First Clinical Data From siRNA Trials in FSHD1 and DM1

Overview

• Sarepta presented early Phase 1/2 results for SRP-1001 and SRP-1003 in a live investor webcast with an audio replay available for one year on its website.
• The company reported initial signs of dose-dependent delivery to muscle and early biomarker activity after a single dose, according to the webcast summary reported by trade coverage.
• Sarepta said the investigational therapies showed a favorable early safety profile with mostly mild to moderate side effects and no dose-limiting safety signals reported.
• Shares of SRPT rose after the release of the early data, reflecting investor interest in the siRNA approach for rare muscle diseases.
• The programs use small interfering RNA to dial down disease-driving genes in FSHD1 and DM1, and Sarepta framed the readout as part of its move beyond Duchenne into muscle, CNS, and cardiac candidates.